Live price temporarily unavailable.
Palisade Bio (PALI) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $16.2K | $260.0K | $260.0K | $15.4K | $13.5K | — | $0 | $250.0K | $0 | $0 |
| Growth (year over year) | +56.0% | +1500.4% | 0.0% | −94.1% | −12.2% | — | — | — | −100.0% | — |
| Operating income | −$20.6M | −$13.3M | −$8.26M | −$8.63M | −$9.30M | −$41.9M | −$15.7M | −$13.1M | −$14.9M | −$18.1M |
| Operating margin | −127027.2% | −5118.1% | −3176.7% | −56071.8% | −68764.8% | — | — | −5228.0% | — | — |
| Net income | −$21.1M | −$15.7M | −$4.92M | −$8.35M | −$10.3M | −$26.6M | −$14.3M | −$12.3M | −$14.4M | −$16.8M |
| Net margin | −129721.8% | −6025.4% | −1894.1% | −54252.6% | −76346.2% | — | — | −4920.0% | — | — |
| EPS (diluted) | −$20493000000.00 | −$9720000000.00 | −$61074000000.00 | −$76950000.00 | −$2790.00 | −$2546.10 | −$247.95 | −$27.01 | −$10.19 | −$0.30 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.2M | $6.67M | $5.79M | $5.11M | $713.0K | $10.5M | $12.4M | $12.4M | $9.82M | $133.4M |
| Total assets | $22.6M | $13.9M | $7.68M | $6.58M | $3.02M | $12.5M | $15.8M | $14.1M | $10.9M | $134.3M |
| Total liabilities | $11.3M | $5.37M | $1.63M | $1.46M | $10.1M | $5.15M | $3.28M | $2.74M | $3.39M | $4.96M |
| Long-term debt | — | — | — | — | $94.0K | $0 | — | — | — | — |
| Shareholders' equity | $11.3M | $8.52M | $6.05M | −$8.33M | −$16.6M | $7.37M | $12.5M | $11.3M | $7.49M | $129.4M |
| Cash flow | ||||||||||
| Operating cash flow | −$15.6M | −$13.4M | −$7.69M | −$7.26M | −$4.77M | −$14.8M | −$13.4M | −$11.1M | −$12.2M | −$10.8M |
| Capital expenditure | $98.1K | $11.4K | $1.71K | — | $6.00K | $0 | $10.0K | $4.00K | $0 | — |
| Free cash flow | −$15.7M | −$13.4M | −$7.69M | — | −$4.77M | −$14.8M | −$13.4M | −$11.1M | −$12.2M | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $0 | $0 | — | $0 | $1 |
| Operating income | −$3.59M | — | −$2.31M | −$2.84M | −$2.92M | — | −$10.7M | −$11.7M |
| Operating margin | — | — | — | — | — | — | — | −1169800000.0% |
| Net income | −$3.49M | — | −$2.23M | −$2.78M | −$2.87M | — | −$9.60M | −$10.6M |
| Net margin | — | — | — | — | — | — | — | −1057400000.0% |
| EPS (diluted) | −$2.32 | — | −$0.47 | −$0.58 | −$0.38 | — | −$0.05 | −$0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $8.04M | $9.82M | $7.23M | $5.42M | $5.23M | $133.4M | $132.6M | $125.2M |
| Total assets | $9.34M | $10.9M | $8.19M | $6.67M | $6.97M | $134.3M | $133.3M | $127.3M |
| Total liabilities | $2.73M | $3.39M | $2.86M | $4.05M | $3.76M | $4.96M | $5.95M | $5.57M |
| Shareholders' equity | $6.61M | $7.49M | $5.33M | $2.62M | $3.21M | $129.4M | $127.4M | $121.7M |
| Cash flow | ||||||||
| Operating cash flow | −$3.13M | — | −$2.33M | −$1.82M | −$3.55M | — | −$3.89M | −$7.60M |
| Capital expenditure | $0 | — | — | — | — | — | — | — |
| Free cash flow | −$3.13M | — | — | — | — | — | — | — |
From Palisade Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Palisade Bio in our feed yet.